Clinical Trial Update: Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) [Phase 1, Phase 2]

View source ↗

Summary

Spevatamig (PT886) is being studied as a monotherapy or in combination with chemotherapy and/or immune checkpoint inhibitors in Phase 1/2 trials for advanced ga…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Spevatamig (PT886)

Snippet

Sponsor: Phanes Therapeutics | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING